Lv5
956 积分 2022-02-22 加入
Ponatinib: An update on its drug targets, therapeutic potential and safety
3天前
已完结
Ponatinib‐review of historical development, current status, and future research
3天前
已完结
Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation
12天前
已完结
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
16天前
已完结
Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission
17天前
已完结
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option
17天前
已完结
Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study
20天前
已完结
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
1个月前
已完结
Management of chronic myeloid leukaemia patients treated with ponatinib in a real‐life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA)
1个月前
已完结
Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network meta-analysis
1个月前
已完结
皖公网安备34019202002308
